Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders
License with Nationwide Children’s Hospital ( NCH ) through the Acquisition of Celenex (NCH Spinout) Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) with Potential to Transform the Lives of 10,000+ Children with Fatal Genetic Diseases              
View HTML
Toggle Summary Amicus Therapeutics Announces Board Appointments
Lynn D. Bleil Appointed to Board of Directors Michael G. Raab Named Lead Independent Director CRANBURY, N.J. , Sept. 11, 2018 (GLOBE NEWSWIRE) --  Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic
View HTML
Toggle Summary Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease
CRANBURY, N.J. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced today regulatory and clinical advancements in its development program
View HTML
Toggle Summary Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2018
CRANBURY, N.J. , Aug. 31, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at two investor conferences in September. Bradley Campbell , President and Chief Operating Officer, and Chip Baird , Chief Financial Officer, will present a corporate
View HTML
Toggle Summary FDA Approves Galafold™ (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease
First Precision and First Oral Medicine for Fabry Disease Approved for 348 Amenable GLA Variants Click to download. Click to download. Galafold is the First New Treatment Option for Fabry Disease in the U.S. in 15+ Years Amicus Therapeutics to Host Conference Call on August 13 at 8 a.m.
View HTML
Toggle Summary Amicus Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Updates
2Q18 Net Product Sales of $21.3M Driven by Galafold ® (Migalastat) Expansion Company Increases FY18 Global Galafold Revenue Guidance to $80M-$90M Pompe Clinical, Regulatory and Manufacturing Activities Continue to Advance Conference Call and Webcast Today at 8:30am ET CRANBURY, N.J. , Aug.
View HTML
Toggle Summary Amicus Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018
CRANBURY, N.J. , July 31, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 7, 2018 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2018 .
View HTML
Toggle Summary Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease
CRANBURY, N.J. , June 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced today regulatory and clinical advancements in its development program for
View HTML
Toggle Summary Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors
Directors Donald J. Hayden, Jr. and Craig A. Wheeler Re-Elected CRANBURY, N.J. , June 08, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the
View HTML
Toggle Summary Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference
CRANBURY, N.J. , June 01, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics , Inc. (Nasdaq:FOLD) announced today that John F. Crowley , Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming Goldman Sachs 39th Annual Global Healthcare Conference
View HTML